November 17, 2017November 17, 2017

FDA Panel Opposes Approving Cipro DPI to Treat Non-CF Bronchiectasis

News

A U.S. Food and Drug Administration (FDA) advisory panel voted not to recommend ciprofloxacin dry powder for inhalation (Cipro DPI), being developed by Bayer, to be approved for the treatment ... Read more

July 18, 2017July 18, 2017

Bayer’s Ciprofloxacin DPI Shows Promise in Treating Non-cystic Fibrosis Bronchiectasis

News

Bayer is conducting two Phase 3 clinical trials evaluating ciprofloxacin Dry Powder for Inhalation (ciprofloxacin DPI) as a treatment for non-cystic fibrosis (non-CF) bronchiectasis, and preliminary data show promising results. The ... Read more